Bristol Myers Q1 revenue $11.5B (+3%); reaffirms 2026 guidance trending upper end

BRISTOL MYERS SQUIBB CO

2026-Q1 EPS reported $1.31 revenue$11,489,000,000

Q1 revenue $11.5B, up 3% YoY (1% ex-FX); Growth Portfolio revenue $6.2B (+12% / +9% ex-FX).
GAAP EPS $1.31; non-GAAP EPS $1.58; both include $(0.03) net impact from Acquired IPRD and licensing.
FY 2026 guidance reaffirmed: revenue ~$46.0-47.5B, non-GAAP EPS $6.05-6.35, trending toward upper end.
CEO highlights strong execution and pipeline milestones ahead for patients and shareholders.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BRISTOL MYERS SQUIBB CO reported the first quarter of 2026 results: revenue $11,489, EPS $1.31. Guidance reaffirmed.

Period: the first quarter of 2026
Revenue: $11,489
EPS: $1.31
Guidance: reaffirmed
Result: reported results

Exact text from the filing

progress into meaningful outcomes for patients and shareholders." First Quarter Results $ in millions, except per share amounts 2026 2025 Change Change Excl. FX** Total Revenues $11,489 $11,201 3 % 1 % Earnings/(Loss) Per Share - GAAP* 1.31 1.20 9 % N/A Earnings/(Loss) Per Share - Non-GAAP* 1.58 1.80 (12) % N/A Acquired IPRD Charges and Licensing Income Net

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

BRISTOL MYERS SQUIBB CO filing history →

Source: SEC EDGAR

accession 0000014272-26-000008

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.